Rebecca J Brown
Overview
Explore the profile of Rebecca J Brown including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
2510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meral R, Celik Guler M, Kaba D, Prativadi J, Frontera E, Foss-Freitas M, et al.
Diabetes Care
. 2025 Mar;
PMID: 40063619
Objective: Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy [GL]) or partial (partial lipodystrophy...
2.
Brown R, Akinci B, Yosef M, Phillips H, Khalatbari S, Sorkina E, et al.
J Clin Endocrinol Metab
. 2025 Feb;
PMID: 39970125
Context: Lipodystrophy syndromes are rare disorders characterized by deficient adipose tissue, leading to insulin resistance, dyslipidemia, and organ system abnormalities. Objective: Our goal was to develop a lipodystrophy severity score...
3.
Meral R, Celik Guler M, Kaba D, Prativadi J, Frontera E, Foss-Freitas M, et al.
medRxiv
. 2025 Jan;
PMID: 39802778
Background: Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodystrophy,...
4.
Garg A, Xing C, Agarwal A, Westfall A, Tomchick D, Zhang X, et al.
Diabetes
. 2024 Dec;
74(3):427-438.
PMID: 39652711
Article Highlights: Molecular genetic defects in some ultra-rare subtypes of familial partial lipodystrophies (FPLs) remain unidentified. We investigated whether novel gene variants explain FPL in some undiagnosed patients. We found...
5.
Brown R, Panter G, Burden N, Weltje L, Wheeler J, Salinas E, et al.
Environ Toxicol Chem
. 2024 Jul;
43(9):1933-1935.
PMID: 38980265
No abstract available.
6.
Burden N, Brown R, Smith R, Brescia S, Goodband T, Guerrero-Limon G, et al.
Regul Toxicol Pharmacol
. 2024 Jul;
151:105671.
PMID: 38968967
Revised information requirements for endocrine disruptor (ED) assessment of chemicals under the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation have been proposed. Implementation will substantially increase...
7.
Brush M, Auh S, Cochran E, Tuska R, Koh C, Kleiner D, et al.
J Clin Endocrinol Metab
. 2024 May;
PMID: 38757950
Context: Leptin replacement therapy with metreleptin improves metabolic abnormalities in patients with generalized lipodystrophy (GLD). Objective: Determine how timing of metreleptin initiation in the clinical course of GLD affects long-term...
8.
Fourman L, Tsai L, Brown R, ORahilly S
N Engl J Med
. 2024 Apr;
390(13):1219-1229.
PMID: 38598578
No abstract available.
9.
Semple R, Patel K, Auh S, Brown R
Commun Med (Lond)
. 2024 Mar;
4(1):57.
PMID: 38532029
No abstract available.
10.
Ceccarini G, Akinci B, Araujo-Vilar D, Beghini M, Brown R, Carrion Tudela J, et al.
Ann Endocrinol (Paris)
. 2024 Mar;
85(4):308-316.
PMID: 38452868
Lipodystrophy syndromes are rare diseases primarily affecting the development or maintenance of the adipose tissue but are also distressing indirectly multiple organs and tissues, often leading to reduced life expectancy...